Microbot Medical Receives U.S. Patent, Broadening Market Opportunities
Patent Grant: Microbot Medical has received a patent from the USPTO for a modular robotic surgical system that features a base and interchangeable tool-receiver units.
Significance of Patent: The company views this patent as crucial, as it allows for future adaptations of the LIBERTY system for a broader range of endovascular procedures.
Market Expansion Potential: This development could significantly increase the Total Addressable Market that Microbot Medical aims to target.
Intellectual Property Portfolio: With this new patent, the company's intellectual property protection in the U.S. now includes 12 granted patents globally and 57 pending applications.
Trade with 70% Backtested Accuracy
Analyst Views on MBOT
About MBOT
About the author
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Ratings Updates: While specific upgrades, downgrades, and initiations are not detailed in the report, the overall changes in ratings may directly impact the stock prices of the companies involved, prompting investors to pay close attention to these shifts.
- Expected Market Reaction: Analyst rating adjustments typically lead to short-term market volatility, and investors should consider these changes as potential buy or sell signals to optimize their portfolios.
- Source Information Reminder: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a more comprehensive market insight to help investors make informed decisions.
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
- First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
- Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
- Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
- Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Ratings Updates: While specific upgrades, downgrades, and initiations are not detailed in the report, the overall changes in ratings may directly impact the stock prices of the companies involved, prompting investors to pay close attention to these shifts.
- Expected Market Reaction: Analyst rating adjustments typically lead to short-term market volatility, and investors should consider these changes as potential buy or sell signals to optimize their portfolios.
- Source Information Reminder: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a more comprehensive market insight to help investors make informed decisions.
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
- First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
- Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
- Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
- Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
